FDA Priority Review

The latest news about FDA Priority Review: headlines, AI summaries and the full story from every source.

• Palvella Therapeutics Reports Q3 GAAP EPS of -$1.70, Exceeding Estimates Seeking Alpha · November 5, 2026, 19:49 UTC
• uniQure Receives FDA Priority Review for AMT-130 with PDUFA Date Set for May 2027 Seeking Alpha · November 4, 2026, 19:05 UTC
• FDA Grants Priority Review for uniQure's Huntington's Disease Gene Therapy Seeking Alpha · November 2, 2026, 16:54 UTC
• FDA Grants Priority Review to Palvella Therapeutics' Qtorin Rapamycin Application Seeking Alpha · October 28, 2026, 15:15 UTC